Frankfurt, Dusseldorf The dialysis group Fresenius Medical Care (FMC), which is listed in the Dax, is facing turbulent times after the surprising departure of CEO Carla Kriwet. Kriwet announced her withdrawal on Tuesday night after only two months. According to company circles, this was preceded by a dispute about the realignment of the dialysis group.
CFO Helen Giza will be his successor with immediate effect. Officially, Fresenius calls “strategic differences” for the change in leadership. The departure is the preliminary highlight of a turbulent year for the dialysis company and its mother Fresenius. Both are under a lot of pressure after several profit warnings.
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue
Read on now
Get access to this and every other article in the
Web and in our app free of charge for 4 weeks.
Continue